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Objectives. We examined whether there is a gender difference in
the improvement of endothelium-dependent vasodilation after
estrogen supplementation.
Background. Estrogen therapy reduces the risk of cardiovascu-
lar events in postmenopausal women, and the augmented release
of endothelium-derived nitric oxide (NO) by estrogens has been
suggested to be one of the mechanisms for the cardioprotective
effects of estrogen.
Methods. With ultrasound technique, we measured the diame-
ter and blood flow of the brachial artery at rest, during reactive
hyperemia after transient occlusion and after nitroglycerin ad-
ministration before and after estradiol supplementation in 15
postmenopausal women (mean 63 years) and in 15 men matched
for age and risk factors for atherosclerosis.
Results. Estradiol supplementation augmented the flow-
mediated vasodilation and serum level of nitrite/nitrate (metabo-
lites of NO) in women (respectively, from a mean 6 SEM of 8.0 6
0.6% to 12.9 6 0.6% [p < 0.01 by analysis of variance (ANOVA)]
and from 64.9 6 8.7 to 93.7 6 9.4 mmol/liter [p < 0.05 by
ANOVA]) but not in men (respectively, from 8.1 6 0.6% to 8.3 6
0.7% and from 57.8 6 6.7 to 60.8 6 5.4 mmol/liter). The increases
in blood flow during reactive hyperemia and in diameter after
nitroglycerin administration were not affected by estradiol sup-
plementation in either men or women.
Conclusions. Estradiol supplementation improves endothelium-
dependent vasodilation in women, probably because of augmented
NO production/release, but not in men. Thus, there may be gender
differences in the effects of estrogen therapy on endothelial
functions and NO production/release.
(J Am Coll Cardiol 1997;30:914–9)
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Life expectancy is greater in women than in men, in large part
because of the lower incidence of cardiovascular death in
women (1). Previous studies (2–4) have suggested that ovarian
hormones, especially estrogens, can through their protective
action against atherosclerosis, reduce the risk of cardiovascular
events in women within the reproductive age group. This
protection is lost with the onset of menopause or after surgical
castration (2,3,5). Thus, estrogen therapy may have beneficial
effects for postmenopausal or castrated women in reducing the
risk of cardiovascular events, as reported previously (2,4–6),
and the American Heart Association consensus panel (7)
recommends estrogen replacement therapy for postmeno-
pausal women with coronary artery disease. However, all
previous studies reported the beneficial effects of estrogen
supplementation in reducing the risk of cardiovascular events
only for women. Therefore, it remains unknown whether
estrogen supplementation also reduces the risk of cardiovas-
cular events in men.
The precise mechanism of the cardioprotective effect of
estrogens on the development of atherosclerosis is unclear at
present. However, several reports (8–10) have shown that
estrogens stimulate the release of endothelium-derived nitric
oxide (NO). This phenomenon may partly contribute to the
cardioprotective action of estrogens with respect to cardiovas-
cular events and the development of atherosclerosis because
NO is known to induce coronary dilation and to suppress
platelet aggregation and migration of monocytes and smooth
muscle cells (11–15). To examine whether there is a gender
difference in the improvement of flow-mediated endothelium-
dependent vasodilation after estrogen supplementation, we
measured the flow-mediated endothelium-dependent vasodi-
lation of brachial arteries in men and women by using an
ultrasound technique before and after estradiol (E2) supple-
mentation. We also measured the serum levels of E2 and
nitrite/nitrate, metabolites of NO, and compared these levels
with the magnitude of endothelium-dependent vasodilation
(15).
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Methods
Study subjects. The study subjects were 15 healthy post-
menopausal female volunteers (mean age 63.6 6 2.6 years)
and 15 healthy male volunteers matched for age and risk
factors for atherosclerosis (mean age 63.1 6 0.7 years).
Women were eligible if menopause had occurred at least 1
year previously (mean age at which the women reached
menopause 51.2 years [range 47 to 55]). Menopause was
confirmed by measuring serum follicular-stimulating hormone
levels. No subject had received hormone replacement therapy
for $2 months before the study. All subjects were asymptom-
atic, normotensive, nondiabetic and nonsmoking. None had
congestive heart failure or any other serious disease. The
subjects’ characteristics are shown in Table 1. All subjects were
studied before and after supplementation of 17-beta estradiol
(Estraderm TTS, 4 mg, Ciba, Basel, Switzerland) transder-
mally for 36 h. Written informed consent was obtained from all
volunteers before the study. The study was in agreement with
the guidelines approved by the ethics committee at our insti-
tution.
Study design. In this study, flow-mediated vasodilation and
nitroglycerin-induced vasodilation of the brachial artery were
measured by two skillful examiners who did not know whether
their study was done before or after E2 supplementation. We
excluded subjects with inadequate scan quality of either bra-
chial artery before the study. All studies were performed in a
quiet temperature-controlled room (22° to 23°C). During the
study, blood pressure was monitored in the right arm every
2 min by an automated blood pressure recorder. All study
subjects were right-handed.
The vasodilator responses in the brachial arteries were
measured by ultrasound technique. The validity of the method
has been confirmed by our previous studies and others (16–
20). Briefly, the diameter of the left brachial arteries was
measured from B-mode ultrasound images with the use of a
7.5-MHz linear array transducer (SSH-160A ultrasound sys-
tem, Toshiba Corp., Tokyo, Japan). Flow velocity in the
brachial arteries was measured by using a pulsed Doppler
signal at a 70° angle to the vessel, with the range gate (1.5 mm)
in the center of the artery. The brachial arteries were scanned
in the antecubital fossa in longitudinal fashion. Depth and gain
settings were optimized at the beginning of the study and were
kept constant throughout the recording period. When a satis-
factory transducer position was found, the surface of the skin
was marked, and the arm remained in the same position
throughout the study.
The subjects lay quietly for 10 min before the first scan.
After baseline measurements of the diameter and flow velocity
in the brachial arteries were obtained, a blood pressure cuff
placed around the forearm was inflated with a pressure of 250
to 300 mm Hg. After 4.5 min, the cuff was released. The
diameter and flow velocity were continuously measured be-
tween cuff inflation and after cuff deflation. Thereafter, the
subjects lay quietly for 15 min. After confirmation that the
diameter and the flow velocity returned to the baseline levels,
sublingual nitroglycerin (0.3 mg) was administered, and 3 to
4 min later, the last measurements were made.
Corretti et al. (19) reported that, compared with 5 mins of
arterial occlusion, 1 and 3 min of arterial occlusion were
inadequate to elicit statistically significant vasodilation re-
sponses. Furthermore, Celermajer et al. (16,17) reported that
4.5 mins of arterial occlusion was adequate to elicit statistically
significant vasodilation responses. Thus, we used 4.5 min of
arterial occlusion to evaluate the flow-mediated endothelium-
dependent vasodilation.
The ultrasound images were recorded on a super-VHS
video cassette recorder (BR-S601M, Victor Corp., Tokyo,
Japan) and arterial diameters were measured at a fixed dis-
Abbreviations and Acronyms
ANOVA 5 analysis of variance
E2 5 estradiol
NO 5 nitric oxide
Table 1. Clinical Characteristics of Study Subjects Before and After Estradiol Supplementation
Men Women
Before After Before After
Age (yr) 63.1 6 0.7 63.6 6 2.6
Heart rate (beats/min) 62.0 6 2.0 63.4 6 2.1 63.8 6 1.7 64.1 6 2.3
Mean blood pressure (mm Hg) 105.3 6 1.9 107.1 6 2.1 106.7 6 2.3 107.5 6 2.5
Basal arterial diameter (mm) 4.04 6 0.15* 4.06 6 0.16* 3.21 6 0.13 3.20 6 0.14
Basal blood flow (ml/min) 279.3 6 30.1* 280.5 6 28.7* 165.2 6 19.1 167.3 6 18.7
Increase in blood flow during
reactive hyperemia (%)
241.5 6 29.9 245.6 6 28.8 249.5 6 27.5 247.6 6 29.3
Total cholesterol (mg/dl) 155.7 6 6.7 157.3 6 7.0 156.8 6 6.0 155.9 6 6.5
HDL cholesterol (mg/dl) 46.2 6 1.8 45.6 6 2.0 48.3 6 2.8 47.1 6 2.1
LDL cholesterol (mg/dl) 97.2 6 6.2 98.1 6 5.9 96.4 6 5.7 97.0 6 6.1
Triglyceride (mg/dl) 58.7 6 8.4 57.2 6 7.9 59.1 6 7.1 58.4 6 6.9
*p , 0.01 versus before and after estradiol supplementation in women. Data are expressed as mean value 6 SE.
HDL 5 high density lipoprotein; LDL 5 low density lipoprotein.
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tance from an anatomic marker with ultrasound calipers by two
independent observers who did not know whether the study
subject was male or female or whether the study was done
before or after E2 supplementation. Measurements were taken
from the anterior to the posterior interface between the media
and adventitia (“m” line) at end-diastole, incident with the R
wave on a continuously recorded electrocardiogram (16,17,19–
21). The diameter at four cardiac cycles was analyzed for each
scan, and the measurements were averaged. The diameter
measurements for reactive hyperemia were taken 45 to 90 s
after cuff deflation to measure peak diameter (19). The
responses of the vessel diameters to reactive hyperemia and
nitroglycerin were expressed as a percent increase of the
baseline value of the diameter. Blood flow was calculated by
multiplying the velocity-time integral of the Doppler flow
signal by heart rate and the vessel cross-sectional area. The
percent of increase in brachial blood flow observed immedi-
ately after cuff deflation was calculated as the maximal flow
recorded within the 1st 15 s after cuff deflation divided by the
flow at baseline (16,17,19,20).
In our studies, the repeated measurements of rest arterial
diameter had an interobserver variability of 0.05 6 0.02 mm,
and an intraobserver variability of 0.02 6 0.02 mm. When these
studies were performed at the same time on 2 separate days in
20 control subjects, the between-occasions within-patient dif-
ference for the measurements of arterial diameter during
reactive hyperemia was 0.05 6 0.04 mm.
Blood sampling and assays. Blood samples were obtained
from all study subjects on the study day while the subjects were
in the fasting state. Serum E2 concentrations were measured
by a specific immunoradiometric assay for E2 (Diagnostic
Products Corp.) (20,22). Serum total cholesterol and triglycer-
ide concentrations were measured enzymatically, and serum
high density lipoprotein (HDL)-cholesterol concentration was
measured by heparin-Ca21/Ni21 precipitation (23). Nitrite/
nitrate, stable metabolites of NO, were measured with an
autoanalyzer (flow injection analyzer, TCI-NOX1000, Tokyo
Kasei Kogyo, Tokyo, Japan) that used a method based on the
Griess reaction (15,20,24). Briefly, the samples were passed
through a column containing copper-coated cadmium, which
reduced all nitrate to nitrite. The nitrite then was detected
when it reacted with Griess reagent (24). Absorbance was
measured at 540 nm by spectrophotometer.
Statistical analysis. The changes in variables were assessed
by two-way analysis of variance with repeated measures fol-
lowed by post hoc testing with the Scheffe´ test. Statistical
significance was defined as p , 0.05.
Results
All study subjects tolerated the studies well. E2 supplemen-
tation did not make any difference in heart rate, mean blood
pressure, lipid profile or percent increase in blood flow during
reactive hyperemia in either the men or the women (Table 1).
The percent increase in arterial diameter during reactive
hyperemia was comparable in the men and the women before
E2 supplementation (8.1 6 0.6% vs. 8.0 6 0.6%, p 5 0.97).
After E2 supplementation, the percent increase in arterial
diameter during reactive hyperemia was augmented in the
women (from 8.0 6 0.6% to 12.9 6 0.6%, p , 0.01) but not in
the men (from 8.1 6 0.6% to 8.3 6 0.7%, p 5 0.85) (Fig. 1).
The effect of E2 supplementation on arterial dilation during
reactive hyperemia in the women was significantly different
from that in the men (p , 0.01). The percent increase in
arterial diameter after nitroglycerin administration was com-
parable in the men and the women before and after E2
supplementation (before E2, 19.7 6 2.0% vs. 19.7 6 2.8%, p 5
0.97; after E2, 20.3 6 1.6% vs. 21.6 6 2.6%, p 5 0.60). E2
supplementation did not alter the increase in diameter after
nitroglycerin administration in either the men or the women
(men, from 19.7 6 2.0% to 20.3 6 1.6%, p 5 0.46; women,
from 19.7 6 2.8% to 21.6 6 2.6%, p 5 0.25) (Fig. 2). The
serum level of nitrite/nitrate was comparable between the men
and the women before E2 supplementation (64.9 6 8.7 vs.
57.8 6 6.7 mmol/liter, p 5 0.61). After E2 supplementation, the
serum level of nitrite/nitrate was increased in the women (from
64.9 6 8.7 to 93.7 6 9.4 mmol/liter, p , 0.05) but not in the
men (from 57.8 6 6.7 to 60.8 6 5.4 mmol/liter, p 5 0.57) (Fig.
3). The effect of E2 supplementation on serum nitrite/nitrate
levels in the women was significantly different (p , 0.05) from
that in the men. There was no statistical difference in the serum
E2 level before E2 supplementation between the men and the
women (29.7 6 7.0 vs. 19.7 6 2.8 pg/ml, p 5 0.21). The serum
E2 level increased after E2 supplementation in both groups
(men, from 29.7 6 7.0 to 88.3 6 6.6 pg/ml, p , 0.01; women,
from 19.7 6 2.8 to 94.6 6 9.6 pg/ml, p , 0.01), and there was
no difference between the men and the women (p 5 0.59) in
the serum level of E2 after E2 supplementation (Fig. 4).
Figure 1. Bar graph showing the percent increase in arterial diameter
during reactive hyperemia in men and women before (striped bars)
and after (solid bars) E2 supplementation. See text for details. Data
are expressed as mean value 6 SE. *Significant effect of estradiol
supplementation compared with values in male subjects (p , 0.01 by
ANOVA).
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Discussion
The present study demonstrated that short-term E2 supple-
mentation augmented dilation of the brachial artery during
reactive hyperemia after transient occlusion and increased the
serum level of nitrite/nitrate in the women but not in the men.
The response of arterial diameter to nitroglycerin (an
endothelium-independent vasodilator) did not change after E2
supplementation in either the men or the women. Further-
more, the response of arterial diameter to nitrovasodilators
has been reported (20,22,25) to be unaffected by the physio-
logic level of serum estrogens. Coronary risk factors, such as
serum lipid profiles and blood pressure, are known to affect
flow-mediated arterial dilation (16,17). However, they are
unlikely to have modified the present results, because they
were not changed, regardless of E2 supplementation, in either
the men or the women. Thus, the present results suggest that
short-term E2 supplementation may possibly augment flow-
mediated endothelium-dependent dilation of the brachial ar-
teries in women but not in men. Endothelium-dependent
vasodilation has been shown to play a crucial role in the
regulation of vascular tone (26–29). Furthermore, blood flow
and shear stress cause production and release of endothelium-
derived NO, which plays an important role in flow-mediated
endothelium-dependent arterial dilation (28–31). Estrogens
increase calcium-dependent NO synthase activity in vascular
endothelium (9). In the present study, the serum level of
nitrite/nitrate, stable metabolites of NO (15), was increased
after E2 supplementation in the women. This finding is in
agreement with a previous study (10) showing that basal
release of NO from endothelium-preserved aortic rings of the
female rabbits is regulated by ovarian hormones. Furthermore,
we (20) previously reported that the flow-mediated endothelium-
dependent vasodilation and the serum nitrite/nitrate level
varied in parallel with serum estrogen levels during the men-
strual cycle in premenopausal healthy women. Both endothelium-
dependent vasodilation and serum nitrite/nitrate levels in
postmenopausal women are lower than those in the follicular
phase in premenopausal women. In the present study, the
depressed arterial reactivity was normalized with increasing
serum nitrite/nitrate levels when serum E2 levels were in-
creased to follicular levels after E2 supplementation in the
postmenopausal women but not in the men. Thus, our present
findings strongly suggests that short-term estrogen supplemen-
tation causes induction of NO synthase and improves flow-
mediated endothelium-dependent dilation of the brachial ar-
teries in women.
Mechanisms of the gender differences in the improvement
of endothelial functions after E2 supplementation. The pre-
cise mechanism for the gender differences in the improvement
of flow-mediated endothelium-dependent vasodilation after
E2 supplementation remains undetermined in the present
study. Treatment with various antioxidant agents restores
Figure 2. Bar graph showing the percent increase in arterial diameter
after sublingual nitroglycerin administration in men and women before
(striped bars) and after (solid bars) E2 supplementation. See text for
details. Data are expressed as mean value 6 SE.
Figure 3. Bar graph showing the level of serum nitrite/nitrate in men
and women before (striped bars) and after (solid bars) E2 supple-
mentation. See text for details. Data are expressed as mean value 6
SE. *Significant effect of estradiol supplementation compared with
values in male subjects (p , 0.05 by ANOVA).
Figure 4. Bar graph showing the variation in serum E2 concentrations
before (striped bars) and after (solid bars) E2 supplementation. See
text for details. Data are expressed as mean value 6 SE.
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endothelium-dependent vasodilation, and estrogens have
shown antioxidant activity in experimental studies (32,33).
However, in the present study, flow-mediated endothelium-
dependent vasodilation of the brachial arteries was increased
after 36 h of E2 supplementation in the postmenopausal
women but not in the men. Collins et al. (34) reported that
short-term administration of E2 modulates coronary artery
responses induced by acetylcholine (an endothelium-dependent
vasodilator) in women but not in men. These findings of a
gender-specific benefit of estrogens suggest that the rapid
improvement in endothelial function cannot be accounted for
by the proposed receptor-independent actions of estrogens,
such as the antioxidant activity reported in experimental
animal studies (32,33). Weiner et al. (9) reported that the
calcium-dependent NO synthase activity was increased in
female pigs but not in male pigs after 5 days of estrogen
supplementation. They also reported that, although calcium-
dependent NO synthase activity was not increased in male pigs
after 5 days of estrogen supplementation, it was increased after
10 days of estrogen supplementation. Thus, one possible ex-
planation for these observations is that the number or avail-
ability of estrogen receptors is initially too low in most tissues
of the male pigs and requires a period of estrogen prim-
ing (35). The effect of long-term E2 supplementation on the
modulation of arterial tone in men remains unclear from
the present study. We need further study to clarify the effect
of the long-term E2 supplementation on the modulation of
arterial tone in humans.
Reactive hyperemia after temporary interruption of the
blood flow may result from an interplay between physical
(myogenic) and local metabolic factors, including prostaglan-
dins and adenosine (36,37). Increased wall shear stress due to
the increase in blood flow results in the production of the
endothelium-derived vasodilators, including NO (30,38). We
and others (39,40) have shown that after transient arterial
occlusion, NO plays a significant role in the duration of
hyperemia or flow debt repayment but not in the peak reactive
hyperemia. That may be why the increase in peak blood flow
before and after E2 supplementation was comparable in the
men and the women despite the gender differences in the
flow-mediated endothelium-dependent vasodilation.
Clinical implications. Endothelium-derived NO inhibits
platelet aggregation and development of atherosclerosis (11–
15). Impairment of endothelium-dependent vasodilation has
been shown (41–43) to be related to the pathophysiology of
vascular diseases. A previous report (18) showed a close
relation in the magnitude of endothelium-dependent vasodila-
tion between the coronary and brachial arteries. Thus, the
present study suggests that, in women, E2 supplementation
may prevent various cardiovascular diseases such as coronary
artery spasm, which has been shown (44,45) to be partly
mediated by the dysfunction of endothelium-regulated arterial
tone.
Differences in endothelial functions between premeno-
pausal and postmenopausal women. The postmenopausal
women in this study demonstrated an 8% increase in arterial
diameter during reactive hyperemia before E2 supplementa-
tion, in contrast, despite similar serum E2 levels, the premeno-
pausal women at the menstrual phase in our previous study
(20) demonstrated only a 4.9% increase. Because progesterone
and other hormones in addition to estrogens vary during the
menstrual cycle in premenopausal women, we cannot deny the
possibility of effects of the other hormones on the variation of
endothelial functions in premenopausal women. In fact, Miller
and Vanhoutte (46) reported that progesterone antagonized
the stimulatory action of estrogens on the release of
endothelium-derived NO in a canine model. Nevertheless, it is
not clear from the present study why similar levels of estrogens
in women did not result in similar increases in arterial diam-
eter.
Conclusions. The present study showed that E2 supple-
mentation may increase NO production/release and improve
flow-mediated endothelium-dependent vasodilation in women
but not in men. Thus, there may be gender differences in the
effects of estrogen therapy on endothelial functions and NO
production/release in humans.
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